; Whereas limited treatment options and financing life-altering and lifesaving treatments can be challenging for individuals with rare diseases or disorders and their families; Whereas rare diseases and disorders include sickle cell anemia, spinal muscular atrophy, amyotrophic lateral sclerosis, thyroid eye disease, myotonic dystrophy, t-cell prolymphocytic leukemia, Sanfilippo syndrome, microtia, meatal atresia, and conductive deafness; Whereas individuals with rare diseases or disorders can experience difficulty in obtaining accurate diagnoses and finding physicians or treatment centers with expertise in their rare disease or disorder; Whereas the 116th Congress passed the Medicaid Services Investment and Accountability Act of 2019 ( Public Law 116–16 ; 133 Stat. 852), which included provisions for improving access to coordinated, patient-centered health care for children with complex and rare medical conditions in Medicaid, and became effective October 1, 2022; Whereas the FDA and the National Institutes of Health support innovative research on the treatment of rare diseases and disorders; Whereas Rare Disease Day is observed each year on the last day of February; Whereas Rare Disease Day is a global event that was first observed in the United States on February 28, 2009, and was observed in more than 100 countries in 2022; and Whereas Rare Disease Day is expected to be observed globally for years to come, providing hope and information for rare disease and disorder patients around the world: Now, therefore, be it